Supernus Pharma (SUPN) Misses Q1 EPS by 1c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $43 million versus the consensus estimate of $45.33 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist